Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies  by Kim, Chan-Lan et al.
www.elsevier.com/locate/yviro
Virology 320 (2004) 40–51Antigenic characterization of an abnormal isoform of prion protein
using a new diverse panel of monoclonal antibodies
Chan-Lan Kim,a Atsushi Umetani,b Toshio Matsui,b Naotaka Ishiguro,a
Morikazu Shinagawa,a,1 and Motohiro Horiuchia,c,*
aLaboratory of Veterinary Public Health, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan
bObihiro Research Laboratory, Fujirebio Inc., Kawanishi-cho, Obihiro, Hokkaido 089-1111, Japan
cResearch Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, JapanReceived 14 July 2003; returned to author for revision 22 October 2003; accepted 22 October 2003Abstract
We established a panel of monoclonal antibodies (mAbs) against prion protein (PrP) by immunizing PrP gene-ablated mice with the
pathogenic isoform of prion protein (PrPSc) or recombinant prion protein (rPrP). The mAbs could be divided into at least 10 groups by
fine epitope analyses using mutant rPrPs and pepspot analysis. Seven linear epitopes, lying within residues 56–90, 119–127, 137–143,
143–149, 147–151, 163–169, and 219–229, were defined by seven groups of mAbs, although the remaining three groups of mAbs
recognized discontinuous epitopes. We attempted to examine whether any of these epitopes are located on the accessible surface of
PrPSc. However, no mAbs reacted with protease-treated PrPSc purified from scrapie-affected mice, even when PrPSc was dispersed into a
detergent– lipid protein complex, to reduce the size of PrPSc aggregates. In contrast, denaturation of PrPSc by guanidine hydrochloride
efficiently exposed all of the epitopes. This suggests that any epitope recognized by this panel of mAbs is buried within the PrPSc
aggregates. Alternatively, if the corresponding region(s) are on the surface of PrPSc, the region(s) may be folded into conformations to
which the mAbs cannot bind. The reactivity of a panel of mAb also showed that the state of PrPSc aggregation influenced the
denaturation process, and the sensitivity to denaturation appeared to vary between epitopes. Our results demonstrate that this new panel
of well-characterized mAbs will be valuable for studying the biochemistry and biophysics of PrP molecules as well as for the immuno-
diagnosis of prion diseases.
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Introduction by certain post-translational modifications including aTransmissible spongiform encephalopathies (TSEs), so-
called prion diseases, are fatal neurodegenerative diseases
including scrapie in sheep and goats, bovine spongiform
encephalopathy, and Creutzfeldt–Jakob disease (CJD) in
humans (Prusiner, 1991). The causative agent, prion, is
thought to be composed solely, if not entirely, of a
pathogenic isoform of the prion protein (PrPSc). PrPSc is
generated from a host-encoded cellular prion protein (PrPC)0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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forms share the same primary structure (Hope et al., 1986),
PrPSc is distinguished from PrPC by biochemical and
biophysical properties such as high h-sheet content (Pan
et al., 1993; Safar et al., 1993), partial resistance to
protease digestion, and insolubility in nonionic detergent
(Meyer et al., 1986). The conformational transformation
from PrPC to PrPSc requires preexisting PrPSc as a template
and is thought to be a central event in PrPSc formation and
prion replication. However, the molecular mechanism of
the conformational transformation remains unclear. To
elucidate the mechanism, structural information from two
PrP isoforms is needed. At this time, the NMR structure of
a recombinant PrP resembling PrPC has been determined
(Riek et al., 1996), whereas the structure of PrPSc is not yet
known.
C.-L. Kim et al. / Virology 320 (2004) 40–51 41A diverse panel of anti-PrP mAbs is invaluable for
analyzing the difference between PrPC and PrPSc, as well
as for the biochemical and structural analysis of PrP
molecules. To date, many monoclonal antibodies (mAbs)
against PrP have been generated by immunizing with PrPSc
purified from scrapie-affected animals (Barry and Prusiner,
1986; Kascsak et al., 1987; Williamson et al., 1996),
recombinant PrP (Zanusso et al., 1998), synthetic PrP
peptides (Harmeyer et al., 1998; Horiuchi et al., 1995;
O’Rourke et al., 1998), or a PrP expression plasmid (Kra-
semann et al., 1996). Most of the anti-PrP antibodies
developed so far react with linear or discontinuous epitopes
on PrPC and recombinant PrP molecules, as well as with
PrPSc treated with denaturant. These types of anti-PrP anti-
bodies are now widely used for the immuno-detection of
PrPSc. Because these antibodies themselves cannot distin-
guish the two PrP isoforms when the molecules are treated
with denaturant, proteolytic removal of PrPC before
immuno-staining is essential for the detection of PrPSc by
immunoblotting or enzyme-linked Immunosorbent assay
(ELISA). One mAb, designated 15B3, generated by immu-
nizing PrP gene-deficient mice with recombinant bovine
PrP, was reported to recognize a PrPSc-specific conforma-
tional epitope consisting of two PrP molecules (Korth et al.,
1997). However, further characterization of this mAb has
not been published. Recent reports also describe mAbs that
appear to recognize discontinuous epitopes on PrPC but do
not appear to react with PrPSc (Yokoyama et al., 2001).
Further PrPSc- and PrPC-specific antibodies, as well as
additional characterized antibodies to PrP molecules, willFig. 1. Purity of rPrP and PrPSc. (A) Purification of rPrP from bacterial lysates. W
MoPrP23–231 (lane 2) after induction with IPTG for 2 h. Inclusion bodies were p
Inclusion bodies were dissolved in 6 M GdnHCl and applied to Ni2 +-charged IMA
eluted at pH 4.3 was dialyzed against acetate buffer to remove GdnHCl. (B) Forma
intramolecular disulfide bond was collected by reverse-phase HPLC. DTT + and 
mM DTT. (A and B) Coomassie blue staining. (C) Purity of PrPSc fraction from scr
with PK was visualized by sliver staining and the purity was estimated by densitom
markers are in kilodaltons (kDa).help to elucidate the structure–function relationships of PrP,
structural differences between PrPC and PrPSc, and mecha-
nisms of conformational transformation. In addition, new
antibodies showing higher reactivity and specificity than
those currently available would help to improve the sensi-
tivity of PrPSc detection. Although a large number of anti-
bodies against PrP have been generated, it is possible that
undefined epitopes still exist. In this study, we established a
panel of mAbs that covers diverse epitopes on the mouse
PrP molecules by immunizing PrP / mice with either
recombinant mouse PrP or PrPSc purified from scrapie-
affected mouse brains. The mAbs could be at least divided
into 10 groups based on fine epitope mapping. Finally, we
discuss how this panel of well-characterized mAbs will be
useful for analyzing the molecular properties of PrP as well
as for diagnostic purposes.Results
Production of monoclonal antibodies against PrP molecules
For the immunization of PrP gene-ablated mice, we
prepared rMoPrP as well as PrPSc from brains of scrapie-
affected mice. Fig. 1 shows the purity of rMoPrP and PrPSc.
rMoPrP23–231 expressed by pRSETB in E. coli formed
inclusion bodies (Fig. 1A). The rMoPrP23–231 recovered
from inclusion bodies was dissolved with 6 M GdnHCl, and
further purified with Ni2 +-charged IMAC. After dialysis,
rMoPrP possessing an intramolecular disulfide bond washole lysates of E. coli transformed with pRSETB (lane 1) and pRSETB/
repared from whole bacterial lysates (lane 3) for partial purification of rPrP.
C. The rPrP was eluted with a stepwise pH gradient (lanes 4–6), and rPrP
tion of intramolecular disulfide bonds. After the dialysis, rPrP possessing an
indicates purified rPrP dissolved with sample buffer with and without 100
apie-affected mouse brains. The PrPSc fraction treated (+) and untreated ( )
etric analysis by using Atto Densitograph (Atto Co. Ltd.). Molecular mass
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prepared from brains of scrapie-affected mice was estimated
to be >70% pure even without PK treatment (Fig. 1C), and a
bioassay revealed that this fraction was estimated to contain
more than1011 LD50/mg from our dose–incubation time
standard curve for Obihiro strain (data not shown). These
PrP fractions were used for immunization of PrP gene-
ablated mice, and splenocytes from immunized mice were
fused with myeloma cells. Hybridomas positive for both
rMoPrP and MoPrPSc, or those positive either for rMoPrP or
MoPrPSc, were selected. Finally, we established 4, 10, and
15 hybridomas using rMoPrP23–231, rMoPrP89–231 or
MoPrPSc, respectively, as the immunogen (Table 1).
Epitope analyses
To determine the epitopes recognized by the mAbs, we
first examined their reactivity to various mutant rPrPs by
ELISA. Based on their reactivity, the mAbs were divided
into seven groups (Table 1). The mAbs in group I did not
react with rMoPrP lacking the N-terminal region, indicating
that their epitopes are located in residues 23–89. Group II
mAbs reacted with all rMoPrPs except for rMoPrP155–231,
indicating that they recognize the regions between residues
89 and 155. Group III consists of mAb 43C5, which reacted
with all rMoPrPs, suggesting that its epitope is located
between residues 155 and 167. The mAbs in group IV did
not react with mutants lacking the C-terminus but reacted
with other mutants, indicating that they recognize the
epitopes on the C-terminal part of PrP molecule. The mAbs
in group V reacted with rMoPrP155–231 but not with
rMoPrP23–214. In addition, these mAbs did not react with
point mutants rHaPrPC179A and rHaPrPC214A in which
the cysteines at residues 179 and 214, respectively, were
replaced with alanine. The mAbs reacted equally withTable 1
Grouping of mAbs based on the reactivity to rPrP deletion and point mutants
Group mAba (Isotypeb) rPrP used as antigenc
rMoPrP23–167 rMoPrP23–214
I 8(2b), 37(2b), 40(2b),
106(2b), 110(2b), 162(2a)
+ +
II 13(2b), 32(2a), 118(2b),
132(G1), 149(2b), 31C6(G1)
+ +
III 43C5(G1) + +
IV 39(2b), 147(2b)  
V 66(G1), 31B1(G1), 31B5(G1),
42B4(G1), 42D2(G1), 42D6(G1),
44A2(G1), 44A5(G1), 44B1(2a),
44B5(G1)
 
VI 23D9(G1), 42D3(G1), 44B2(G1)  
VII 72(G1) + 
a MAbs named only with numbers were obtained by using MoPrPSc as the immuno
using rMoPrP as the immunogen Among the latter, mAbs starting with 23 or 31,
rMoPrP89–231, respectively.
b G1, IgG1; 2a, IgG2a; 2b, IgG2b.
c Examined by ELISA.rMoPrP23–231 and rHaPrP23–231 (data not shown), indi-
cating amino acid differences between Mo and HaPrP did
not influence the reactivity. These facts suggest that mAbs
in groups V recognize discontinuous epitopes, including the
region within residues 155–231, and that the epitopes are
dependent on the intramolecular disulfide bond in the PrP
molecule. The mAbs in group VI reacted with rMoPrP89–
231, but neither reacted with rMoPrP155–231 nor point
mutants of rHaPrP, suggesting that the epitope for these
mAbs include the region within residues 89–231 and also
are dependent on the intramolecular disulfide bond. The
reactivity of mAb 72 (group VII) was difficult to figure out
the epitope. It reacted with rMoPrP89–231 and 23–167,
suggesting that the epitope is located within residues 89–
167. However, the mAb did not react with rMoPrP23–214,
rHaPrPC179A, or rHaPrPC214A, but reacted with
rHaPrP23–231, again suggesting that the epitope depends
on the presence of the intramolecular disulfide bond.
Further precise epitope mapping was carried out by
pepspots analysis (Fig. 2). The reactivity of the group I
mAbs revealed that they recognize a portion of octa-peptide
repeat in N-terminus, although there is some difference in
the amino acid sequence recognized by these mAbs. Based
on the reactivity (Fig. 2A), the epitope for mAb 8 was
WGQPHG at aa 56–61, 64–69, 72–77, and 80–85. mAbs
110 and 37 reacted with peptides 16–19 and 28–31,
indicating that the recognized sequence is PHGGGWG at
aa 59–65 and 83–89 (Fig. 2B). mAbs 40, 106, and 162
showed broad reactivity to peptides ranging from 13 to 33
(Fig. 2C). The reaction to peptides including 17 to 19 and
29 to 33 the most intense, suggesting that the major
recognition sequence for these mAbs is PHGGGWGQ at
aa 59–66 and 83–90, although the minimum required
sequence appears to be WGQ. The group II mAb 132
reacted with peptides from 47 to 49, which share residuesrMoPrP89–231 rMoPrP155–231 rHaPrPC179A rHaPrPC214A
  + +
+  + +
+ + + +
+ + + +
+ +  
+   
+   
gen, others named with a combination of numbers and letters were obtained
and 42, 43 or 44 were obtained by immunization with rMoPrP23–231 and
Fig. 2. Pepspot analysis. Bars on the right sides indicate lines of peptide spots. The first through fourth lines contain 20 spots per line, while fifth line contains
19 spots. (A) mAb 8 (group I); (B) mAb 110 (group I); (C) mAb 162 (group I); (D) mAb 132; (group IIa); (E) mAb 118 (group IIb); (F) mAb 31C6 (group IIc);
(G) mAb 32 (group IId); (H) mAb 43C5 (group III); (I) mAb 147 (group IV); (J) mAb 72 (group VII); (K) mAb P1–284 (anti-parvovirus mAb, negative
control).
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(group II) reacted with peptides from 55 to 58, which
contain the fragment corresponding to residues 137–143,
MIHFGND (Fig. 2E). The mAb 31C6 (group II) reacted
with peptides from 58 to 61, which share in common
residues 143–149, DWEDRYY (Fig. 2F). mAbs 32 and
149 (group II) reacted with five peptides from 59 to 63 that
share a common sequence RYYRE, residues 147–151 (Fig.
2G). The mAb 43C5 (group III) reacted with 10 continuous
spots but intense reactivity was observed to four peptides
from 68 to 71, which contain the fragment corresponding to
residues 163–169, RPVDQYS (Fig. 2H). This result is
consistent with the epitope analysis of mutant recombinant
PrPs. mAbs 39 and 147 (group IV) reacted with peptides 98
and 99, which correspond to the extreme C-terminus of PrP
molecules, residues 219–229, KESQAYYDGRR (Fig. 2I).
The mAbs in groups I–IV reacted with rHaPrPC179A and
rHaPrPC214A in the ELISA (Table 1) and PrPSc in immu-
noblot analysis (Fig. 3), indicating that these mAbs recog-
nize linear epitopes. mAb 72 appeared to recognize
discontinuous epitope based on the reactivity to mutant
rPrP (Table 1), although the mAb reacted with peptides
60 and 61, which share residues 143–153 (Fig. 2J).
Based on the fine epitope mapping by pepspot analysis,
the mAbs in group II of Table 1 can be separated into four
groups, designated IIa–IId. Together, the mAbs produced in
this study can be divided into at least 10 groups; 7 that
recognize linear epitopes, and 3 that recognize discontinu-
ous epitopes (Table 2).
Species specificity of mAbs
We next examined the specificity of the mAbs by ELISA
using species-specific versions of rMoPrP, rHaPrP, rShPrP,
and rBoPrP. Most of the mAbs reacted with the rPrP fromall four species (hamster, bovine, mouse and ovine), while
the following mAbs showed obvious species-specific reac-
tivity: mAbs 13 and 118 in group IIb, mAbs 39 and 147 in
group IV, and mAb 66 reacted to Mo and HaPrP, while
mAbs 42D2 and 44B5 showed intense reaction to Mo and
HaPrP, moderate reaction to ShPrP but no reaction to BoPrP
(data not shown).
Fig. 3 shows the reactivity to MoPrPSc, ovine PrPSc
(ShPrPSc), and bovine PrPSc (BoPrPSc) in immunoblot anal-
ysis. mAbs 110, 132, 118, 31C6, 32, 43C5, and 147, which
recognize linear epitopes, reacted with PrPSc prepared from
brains of the disease-affected animals. Surprisingly, mAbs
44B1 and 72, which appeared to recognize discontinuous
epitopes, showed an intense reaction to PrPSc in immuno-
blotting. The species-specific reactivities of mAbs 132, 118,
32, 43C5, 147, 44B1, and 72 are consistent with the results
from ELISA; mAbs 118 and 147 only reacted with MoPrPSc
while other mAbs reacted with PrPSc from the other three
species. In contrast to the results from ELISA, mAb 31C6
only reacted with MoPrPSc and mAb 110 reacted with Mo
and ShPrPSc but not with BoPrPSc in immunoblot analysis.
Reactivity of panel mAbs to purified PrPSc
To determine whether any of the antibody-reactive epit-
opes are exposed in the infectivity-associated PrPSc, we
examined the reactivity of mAbs to purified MoPrPSc by
ELISA. A set of three PrPSc preparations, PK-untreated and
non-denatured, PK-treated and non-denatured, and PK-trea-
ted and denatured, was used for each mAb (Fig. 4). All the
mAbs reacted with PK-untreated non-denatured PrPSc, al-
though the reactivity was lost when PrPSc was treated with
PK. However, the mAbs regained reactivity when the PK-
treated PrPSc was denatured with GdnHCl. These results
suggest that the inability of the antibodies to react to PK-
Fig. 3. Species specificity in Western blot analysis. Crude preparations of mouse (Mo), bovine (Bo), and sheep (Sh) PrPSc were prepared as described elsewhere
(Grathwohl et al., 1997) and were separated by SDS-PAGE and transferred onto PVDF membranes. Brain tissue equivalents of 25 mg, 500, and 125 Ag were
loaded for Mo, Bo, and Sh PrPSc, respectively. The blots were stained with B-103 rabbit polyclonal antibodies (Horiuchi et al., 1995) or mAbs as indicated.
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appears that the epitopes on PK-treated PrPSc are cryptic. A
considerable amount of PK-sensitive PrP, including PrPC, is
co-purified during PrPSc purification in the absence of PK
treatment (Caughey et al., 1995). Therefore, it is likely thatTable 2
Characterization of mAbs against PrP
Group mAb Epitopea
position
(amino acid)
I 8, 37, 40, 106, 110, 162 56–90
IIa 132 119–127
IIb 13, 118 137–143
IIc 31C6 143–149
IId 32, 149 147–151
III 43C5 163–169
IV 39, 147 219–229
V 66c, 31B1, 31B5, 42B4,
42D2, 42D6, 44A2, 44A5,
44B1, 44B5c
155–231
VI 23D9, 42D3, 44B2 89–231
VII 72 89–231 (143–153)
a L, linear epitope; DC, discontinuous epitope.
b Treatments of PrPSc are as described in Fig. 4.
c MAbs 66 and 44B5 reacted with rPrP but did not react with the three PrPSc prereaction of the mAbs with PK-untreated non-denatured
PrPSc accounts for the reaction to PK-sensitive PrP that
exposes these epitopes on its accessible surface. Further-
more, the epitopes recognized by our panel of mAbs do not
appear to be exposed on the surface of the PK-resistant coreReactivity to PrPSc in ELISAb
L/DC PK( )
GdnHCl( )
PK(+)
GdnHCl( )
PK(+)
GdnHCl(+)
L +  +
L +  +
L +  +
L +  +
L +  +
L +  +
L +  +
DC +( )c  +( )c
DC +  +
DC +  +
parations.
Fig. 5. Sedimentation analysis of DLPC-treated PrPSc. DLPC-treated (lanes
1–4) and untreated PrPSc (lanes 5–8) were digested by PK and then
subjected to sedimentation analysis. Centrifugation at 10000  g yielded
pellet (lanes 1 and 5) and supernatant (lanes 2 and 6) fractions. The
supernatants were further subjected to ultracentrifugation at 100000  g to
generate pellet (lanes 3 and 7) and supernatant (lanes 4 and 8). The PrPSc in
each fraction was detected by immunoblot analysis.
Fig. 4. Reactivity of mAbs to PrPSc fraction in ELISA. A set of three wells were used for each mAb: after the adsorption of purified PrPSc fraction, first well
was neither treated with PK nor with GdnHCl [PK( ), GdnHCl( )], second well was treated with 40 Ag/ml PK for 60 min at 37 jC [PK(+), GdnHCl( )],
and third well was treated with PK and then further treated with 6M GdnHCl for 60 min to denature PrPSc [PK(+), GdnHCl(+)]. mAbs indicated in the figure
were used as a representative for each group in Table 2. Dotted line indicates the cut-off value [An average OD450 value of negative control monoclonal
antibody plus 5 times standard deviation (n > 4)].
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denaturation of PK-resistant core of PrPSc.
Reduction of PrPSc aggregate size does not expose cryptic
epitopes
Purified PrPSc forms relatively large aggregates that can
be precipitated by centrifugation at 10000  g. We were
concerned that the large aggregates themselves affect the
antibody accessibility to PrPSc. To address this concern, we
attempted detergent-lipid-protein complex (DLPC) treat-
ment, which can reduce aggregate size without loss of
infectivity (Gabizon et al., 1987). As shown in Fig. 5,
nearly all of the purified PrPSc was present in the pellet after
centrifugation at 10000  g for 10 min, although more
than the half of DLPC-treated PrPSc remained supernatant.
Further centrifugation at 100000  g of the soluble DLPC-
treated PrPSc resulted in its precipitation. These results show
that the DLPC treatment reduces the size of PrPSc aggre-
gates without significant a loss of PK resistance. As
described above (Fig. 4), mAbs did not react with PK-
treated, DLPC-untreated PrPSc unless it was denatured (at 0
M GdnHCl in Fig. 6). Although all the mAbs except for
mAbs 110, 132, and 32 faintly reacted with DLPC-treated
PrPSc without denaturation (OD450 < 0.17 at 0 M
GdnHCl), none of the mAbs showed a significant increase
in reactivity to DLPC-treated PrPSc compared with DLPC-
untreated PrPSc. These results suggest that the reduction ofaggregate size by DLPC is not sufficient to expose cryptic
epitopes on PrPSc.
Exposure of cryptic epitopes by denaturation
The reduction of PrPSc aggregate size by DLPC did not
result in the efficient exposure of the hidden epitopes. In
Table 3
Reactivity of mAbs to partially denatured PrPSc
DLPC-untreated DLPC-treated
mAb OD450 at
2M/6M GdnHCl Ratio
OD450 at
2M/6M GdnHCl Ratio
110 0.084/0.789 0.10 0.529/0.994 0.53
132 0.084/1.074 0.08 0.560/1.235 0.45
118 0.295/1.292 0.19 0.488/1.320 0.37
31C6 0.367/2.031 0.18 1.211/2.085 0.58
32 0.167/0.872 0.19 0.305/0.653 0.47
43C5 0.199/1.332 0.15 0.438/1.123 0.39
147 0.271/1.419 0.19 0.581/1.099 0.53
44B1 0.290/1.628 0.18 0.775/1.492 0.52
Fig. 6. Exposure of epitopes by GdnHCl treatment. DLPC-treated or untreated PrPSc was adsorbed to an ELISA plate, digested with PK, and then treated with
the various concentrations of GdnHCl indicated at the bottom of the figure. Average and SD of three independent experiments were plotted. Circles indicate the
DLPC-treated PrPSc, whereas squares indicate DLPC-untreated PrPSc.
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preparations to GdnHCl dramatically increased the reactiv-
ities to all mAbs. This indicates that the dissociation and
denaturation of PrPSc aggregates resulted in pronounced
exposure of epitopes. However, one striking difference in
the reactivity of mAbs was observed especially at lower
GdnHCl concentration: most of the mAbs displayed a
higher reactivity to DLPC-treated PrPSc than to DLPC-
untreated PrPSc at the lower GdnHCl concentrations. This
suggests that DLPC-treated PrPSc may be more sensitive to
denaturant than DLPC-untreated PrPSc.
PrPSc aggregates are thought to undergo partial denatur-
ation in 2 M GdnHCl, and are believed to be almost
completely denatured in 6 M GdnHCl. In parallel with
denaturation of PrPSc, 2 M GdnHCl treatment does not
completely abolish prion infectivity, although >4 M
GdnHCl treatment drastically reduces the infectivity
(Caughey et al., 1997; Prusiner et al., 1993). Table 3 shows
the ratio of OD450 (in Fig. 6) at 2 and 6 M GdnHCl for both
PrPSc preparations. In DLPC-untreated PrPSc, the ratios
varied from 0.08 to 0.19, suggesting that less than 20% of
the epitope for each mAb was exposed following 2 MGdnHCl treatment. In contrast, the ratios increased, varying
from 0.37 to 0.58, following DLPC treatment, indicating
that the reduction of PrPSc size influences the sensitivity to
denaturation. The variation of the ratios may reflect the
difference in the denaturation process for the specific
epitopes. For example, epitopes for mAbs 118 and 43C5
appeared to be more resistant to denaturation by GdnHCl
than other epitopes.
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To generate a diverse panel of mAbs to PrP molecules,
we established a variety of hybridomas by using rMoPrP
and MoPrPSc purified from scrapie-affected mice brain as
immunogens. According to the extensive epitope analyses
using rPrP and pepspot membrane, our mAb panel
contained mAbs recognizing at least seven different linear
epitopes and three discontinuous epitopes. Five of seven
linear epitopes were located within the N-terminal half of
the PK-resistant core of PrPSc (aa 119–127, 137–143,
143–149, 147–151, and 163–169). This region is thought
to undergo a major conformational change from random
coil or a-helix- to h-sheet-rich structure during the con-
version of PrPC to PrPSc. Among the antibodies, mAb 132,
recognizing the epitope aa 119–127 (AVVGGLGGY), is
of particular interest. This region is adjacent to the highly
amyloidogenic sequence AVAAAAVA (aa 112–119) (Gas-
set et al., 1992) and the first short h-strand (aa 128–131).
Studies have shown that this region plays an important role
in the conversion of PrPC to PrPSc (Holscher et al., 1998;
Muramoto et al., 1996). In addition, this region is highly
conserved between mammals and birds, suggesting the
importance of this region in PrPC biology (Wopfner et
al., 1999). Thus, mAb 132 will facilitate studies of how
this region is involved in the conversion process as well as
how PrPC functions. The epitope for mAb 43C5 (aa 163–
169) on PrPC is of also interest because this region, in
conjunction with its C-terminal portion, is thought to be a
binding domain for an unidentified factor tentatively
named protein X, which is expected to act as a molecular
chaperon during the conversion process (Kaneko et al.,
1997). mAb 43C5 will also be a good tool for studying
how this region is involved in the intermolecular interac-
tion. In addition, the first a-helix on PrPC may undergo a
to h conformational change during the conversion process,
although this has not been fully clarified (Zhang et al.,
1995). The mAbs in groups IIb, IIc, and IId recognizing
the first a-helix and its immediate N-terminal portion will
therefore contribute to understanding of structural differ-
ences in this region.
Elucidation of the PrPSc structure is an important prob-
lem to understand the identity of prion. Although the model
structure of PrPSc and its aggregates were recently proposed
from electron crystallography (Wille et al., 2002), their
atomic structures remain to be elucidated. Studies of anti-
body accessibility will help to clarify PrPSc structure
(Kanyo et al., 1999). Our mAbs did not show intense
reactivity to PK-treated PrPSc, which is associated with
prion infectivity, although they strongly react with PrPSc
after denaturation. This suggests none of the epitopes
recognized by our mAb panel are accessible by mAbs on
PrPSc aggregates. The epitope at the C-terminus of PrPSc is
reported to be accessible to antibody (Peretz et al., 1997;
Williamson et al., 1998). In that study, the authors used
DLPC treatment, which can disperse the PrPSc aggregatesinto liposome and reduce particle size of PrPSc aggregates
(Gabizon et al., 1987). Although we confirmed that DLPC
treatment could reduce the PrPSc aggregate size, some
mAbs including one recognizing the C-terminus showed a
trace of reactivity even when we used DLPC-treated PrPSc.
In contrast, denaturation of DLPC-treated PrPSc was re-
quired to expose the cryptic epitopes. This implies that
DLPC treatment might not be sufficient to expose the
cryptic epitope(s) on PrPSc. There are some differences in
experimental conditions between our investigations and
those of Peretz et al. that could explain the differences in
our results. First, they used Sc237 hamster scrapie, while
we used the Obihiro strain of mouse-adapted scrapie.
Second, preparation of PrPSc for ELISA also varied. Peretz
et al. treated PrPSc with PK and the resulting PrP27–30 was
dispersed into liposomes. In contrast, we performed DLPC
treatment first after which DLPC-treated PrPSc was digested
with PK to eliminate PK-sensitive PrP, which is expected to
possess some exposed epitopes. Third, they used streptavi-
din-coated plates to immobilize the PrPSc after biotinyla-
tion, while, in this study, we directly adsorbed PrPSc to the
ELISA plate by possible hydrophobic interaction. Finally,
the antibodies used in the two studies were different.
Although pepspot analysis demonstrated that mAbs 39
and 147 recognize an extreme C-terminal part of PrP, we
used purified IgG instead of a smaller single-strand Fab
fragment. We do not know the reason for the difference in
the mAb reactivity to the C-terminus in our results and
those reported by Peretz et al., it is conceivable that these
differences in the experimental conditions might influence
the results.
Denaturation of PrPSc aggregates caused the exposure
of cryptic epitopes (Serban et al., 1990; Williamson et al.,
1996). Here we observed that the sensitivity to denaturant
varies between the epitopes. In DLPC-treated PrPSc, the
epitopes for mAb 118 and 43C5 appeared to be more
resistant to denaturation as determined by the ratio of OD
at 2 to 6 M GdnHCl treatment. This difference implies
complexity in the inter- or intramolecular interactions
involved in the formation of PrPSc aggregates. It is of
particular interest to examine what kind of inter- or
intramolecular interactions determine prion infectivity or
if exposure of certain epitopes correlates to prion inacti-
vation. Our data also showed that the DLPC-treated PrPSc
is more sensitive to denaturant than DLPC-untreated
PrPSc, indicating that prion inactivation methods are pos-
sibly influenced by the state of PrPSc aggregation and
environment.
The epitopes for mAbs raised against rPrP seemed to be
relatively restricted, and 9 of 14 mAbs recognized a
discontinuous epitope within aa 155–231, indicating this
epitope on rPrP was immunodominant in PrP / mice. In
contrast, the epitopes for the mAbs raised against PrPSc
broadly spanned the PrP molecules. Furthermore, 13 of 14
hybridomas from mice immunized with rPrP secreted
IgG1, although hybridomas secreting IgG2b were predom-
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15). Therefore, the differences in the immunodominant
regions and predominant immunoglobulin subtypes suggest
that the two PrP preparations elicited different type of
immune responses, although the two PrPs share primary
structure and we used the same immunization procedure.
Although PrPSc-specific antibodies are thought to be an
attractive tool for analyzing properties of PrPSc as well as
establishing new diagnostic methods, only one has been
previously reported (Korth et al., 1997). Thus, the unique
immune response against the PrPSc fraction suggests that
the use of an infectivity-associated PrPSc fraction as an
immunogen may help to generate PrPSc-specific antibodies.
In addition, it is still possible that certain regions are
located on the surface of PrPSc as either a linear epitope
or as a PrPSc-specific discontinuous epitope. Actually,
Paramithiotis et al. very recently reported that three amino
acid residues, YYR, possibly located in the second h-
strand, is not antibody accessible on PrPC, although the
region is exposed on the surface of PrPSc (Paramithiotis et
al., 2003). Further generation of mAbs, especially those
specific to PrPSc, will be required for determining the
surface structure of PrPSc.
BSE and vCJD are now global concerns. Because ther-
apeutics for prion diseases are not currently available,
elimination of prion-contaminated foodstuff and biomedical
materials is essential for preventing further spread of the
disease. We have found that some of our mAbs possessed
higher sensitivity for detecting bovine PrPSc than some
commercial-based anti-PrP mAbs, including 6H4 (data not
shown). Further generation of anti-PrP antibodies with
higher affinity and avidity will contribute to enhance the
sensitivity of PrPSc detection methods.Materials and methods
Plasmid construction
The prokaryotic expression vectors pET22b(+) (Nova-
gen) and pRSETB (Invitrogen) were used in these studies.
For the construction of expression plasmids based on
pET22b(+), cDNA encoding mouse (Mo) PrP codons 23–
231 was amplified by PCR with primers MPrP2 and MPrP3,
and genomic DNA encoding sheep (Sh) PrP codons 25–234
was amplified with primers SPrP102 and SPrP103. Ampli-
fied fragments were cloned into the EcoRV site of pBluescr-
pit KS(+) (Stratagene) to confirm nucleotide sequences. The
cloned fragments were excised byMscI and EcoRI digestion
and ligated into the corresponding sites of pET22b(+).
For the construction of expression plasmids based on
pRSETB, cDNA encoding MoPrP codons 23–231 was
amplified with primers MPrP5 and MPrP3. To express
deletion mutants of MoPrP aa 23–167, 23–214, 89–231,
and 155–231, we used primer sets of MPrP5 and MPrP9,
MPrP5 and MPrP11, MPrP10 and MPrP3, and MPrP12and MPrP3, respectively, were used for PCR. Hamster
(Ha) PrP cDNA encoding codons 23–231, ShPrP gene
encoding codons 25–234, and bovine (Bo) PrP cDNA
encoding codons 25–242 were amplified with primer sets
of MPrP5 and MPrP9, SPrP101 and SPrP102, and
BPrP101 and BPrP103, respectively. Amplified fragments
were digested with BamHI and EcoRI and cloned into the
BamHI and EcoRI sites of pRSETB. Nucleotide sequen-
ces of the cloned PrP gene fragments were confirmed
before their expression. To generate the mutant HaPrP
containing a single amino acid substitution at codon 179
(Cys to Ala) or 214 (Cys to Ala), we used the ExSite
PCR-based site-directed mutagenesis kit (Stratagene)
according to the supplier’s instructions. Primer sets of
HPrP1 and HPrP2, and HPrP3 and HPrP4 were used to
introduce the nucleic acid substitution encoding codons
179 and 214, respectively. Primer sequences Primer
sequences were as follows: MPrP2, 5V-AATGGCCA
AAAAGCGGCCAAAGCCTGGA-3 V; MPrP3, 5 V-
GAGAATTCAGCTGGATCTTCTCCCGTCGT-3V; MPrP5,
5V-AAGGATCC GAAAAAGCGGCCAAAGCCTGG-3V;
MPrP9: 5V-GAGAATTC TACTGATCCACTGGCCTG-
GTAG-3 V; MPrP10, 5 V-AAGGATCC GGGCCAAG-
GAGGGGGTACCCATAATC-3V; MPrP11, 5V-GAGAAT
TC AGACGCACATCTGCTCCACCAC-3V; MPrP12, 5V-
AAGGATCC GCGCTACCCTAACCAAGTGTACT-3V;
SPrP101, 5 V-AAGGATCC GAAGAAGCGACCAA-
AACCTGGCGG-3 V; S P r P 1 0 2 , 5 V- TTGAAT TC
AACTTGCCCCCCTTTGGTAATAAG-3V; SPrP103, 5V-
AATGGCCA AGAAGCGACCAAAACCTGGCGG-3V;
B P r P 1 0 1 , 5 V- A AGGATCC GAAGAAGCGAC -
CAAAACCTGGAGG-3V; BPrP103, 5V-TTGAAT TCA
ACTTGCCCCTCGTTGGTAATAAG-3V; HPrP1, 5V-CAC-
GATGCTGTCAACATCACCATCAAG-3V; HPrP2, 5V-
CACAAAGTTGTTCTGGTTGTTGTACTG-3V; HPrP3,
5V-AGATGGCTACCACCCAGTATCAGAAGG-3V; HPrP4,
5V-GCTCCACCACGCGCTCCATTATCTTG-3V(underlines
indicate restriction sites used for cloning, bold indicates
stop codons, and italics indicate nucleotide substitutions
for the mutation of Cys to Ala).
Expression and purification of recombinant PrP (rPrP)
The expression plasmids based on pRSETB and
pET22b(+) were introduced into E. coli BL21(DE3)LysS
and JM109(DE3), respectively. Protein expression was
induced by adding isopropylthio-h-D-galactoside to a final
concentration at 0.4 mM. Two to four hours after induction,
bacterial cells were collected and inclusion bodies were
prepared as described elsewhere (Sambrook et al., 1989).
The inclusion bodies from BL21(DE3)LysS transformed
with pRSETB-based expression plasmids were solubilized
with 6 M GdnHCl in 20 mM phosphate buffer (pH 7.8).
The rPrP was further purified by Ni2 +-immobilized metal
affinity chromatography (IMAC) using Ni2 +-charged Che-
lating Sepharose Fast flow (Amersham Pharmacia) and a
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of 6 M GdnHCl. Inclusion bodies from JM109(DE3) trans-
formed with pET22b(+)-based expression plasmids were
solubilized with 8 M Urea and 20 mM Tris–HCl, pH 8.0.
Next, the urea concentration was reduced to 6 M, and the
mixture was applied to DEAE-Sepharose equilibrated with
6 M Urea and 20 mM Tris–HCl, pH 8.0. The unbound
fraction was saved for further purification. The rPrP in the
eluate from IMAC and the unbound fraction from DEAE-
Sepharose were dialyzed against 10 mM acetate buffer
(ranging from pH 4.4 to 3.6). After the dialysis, rPrP
containing an intramolecular disulfide bond was purified
by reverse-phase HPLC using TSKgel Phenyl-5PW RP
(TOSOH) and a 30–50% linear gradient of acetonitrile
with 0.05% trifluoroacetic acid. The purified rPrP was
lyophilized and dissolved with Mili-Q water at 1 mg/ml
and stored at  20 jC.
Purification of PrPSc and formation of detergent-lipid-
protein complexes (DLPC)
A mouse-adapted scrapie Obihiro strain (Shinagawa et
al., 1985) was used in this study. ICR/Slc female mice
were inoculated intracerebrally with 20 Al of brain ho-
mogenate of Obihiro strain infected-mice and were sacri-
ficed under anesthesia when they showed the clinical
symptoms of the terminal stage of the disease. PrPSc
was purified from the scrapie-affected mice brains without
proteinase K treatment as described by Bolton et al. (1987)
with minor modifications (Caughey et al., 1991). Protein
concentration was determined by DC protein assay kit
(Bio-Rad).
Ten micrograms of purified PrPSc was suspended in 1.6
ml of DLPC buffer containing 2% Sarkosyl, 0.4% phospha-
tidylcholine, 150 mM NaCl, and 50 mM Tris–HCl, pH 8.3.
The suspension was sonicated for five cycles of 2 s with a
Branson Sonifier Contamination-free Ultrasonic Sample
Pre-processing System.
Production of monoclonal antibodies
Purified PrPSc, rMoPrP23–231, or rMoPrP89–231 was
mixed with an equal volume of Freund’s complete adjuvant
and 200 Ag of each PrP was inoculated subcutaneously
into PrP gene-ablated mice (Yokoyama et al., 2001). After
the first immunization, the mice received 100 Ag of the
same PrP preparation with Freund’s incomplete adjuvant
twice every 2 weeks. The booster shot was given intra-
peritoneally with 50 Ag of each PrP preparation in PBS.
Three days after the booster, splenocytes obtained from
immunized mice were fused with P3U1 mouse myeloma
cells using polyethylene glycol 1500 (Roche Diagnostic)
according to the supplier’s instruction, and hybridomas
were selected in HAT medium. Hybridoma culture super-
natants were screened by ELISA using purified PrPSc and
rMoPrP as described below. The hybridomas secretingmAbs were cloned by limiting dilution. The isotypes of
the mAbs were determined using the IsoStrip mouse
monoclonal antibody isotyping kit (Roche Diagnostic).
Large-scale preparations of mAbs were carried out in
INTEGRA CELLine high density culture units (IBS Inte-
gra Biosciences). The supernatants harvested from the units
were concentrated by precipitation with 50% saturated
ammonium sulfate and then purified by size exclusion
chromatography with Superdex-200 HR (Amersham Phar-
macia Biotech).
ELISA
Ninety-six well plates (MaxiSorp, Nunc) were coated
overnight at 4 jC with either 200 ng/well of purified PrPSc
or 100 ng/well of rMoPrP in 50 Al of 20 mM phosphate
buffer, pH 7.0. After adsorption, wells were blocked with
5% fetal bovine serum (FBS) in PBS containing 0.1%
Tween 20 (PBST) for 2 h at room temperature (r.t.), and
then incubated with culture supernatants or antibodies
diluted with 1% FBS in PBST for 1 h. After washing with
PBST, wells were incubated with 100 Al of 1:2500 diluted
HRP-conjugated F(ab’)2 fragment anti-mouse Ig (Amer-
sham Bioscience) for 1 h. Finally, antigen–antibody com-
plexes were detected by adding a substrate solution of 100
Ag/ml of 2,2V-azino-bis(3-ethyl-benzthiazoline-6-sulfonic
acid), 0.04% H2O2 in 50 mM citrate-phosphate buffer, pH
4.0, and the absorbance at 405 nm was measured with a
microplate reader (Multiscan MS-UV, Labsystems). A ready
to use 3,3V,5,5V-tetramethylbenzidine (TMB) was also used
as a substrate, and the absorbance at 450 nm was measured
for TMB.
Immunoblotting
The preparation of PrPSc and immunoblotting were
carried out as described elsewhere (Grathwohl et al.,
1997). The blots were developed with ECLWestern blotting
detection reagents (Amersham Pharmacia) and immunore-
active proteins were detected with X-ray film.
Pepspots analysis
In these studies, we used pepspots membrane to which
an array of 99 overlapping synthetic peptides, cor-
responding to residues 23–231 of mouse PrP, was cova-
lently attached to a cellulose support via carboxyl termini.
Each peptide is 13 amino acid residues long, and there is a
two amino acid shift along the mouse PrP amino acid
sequence from one peptide to the next. The membrane
was blocked with 5% skim milk and 5% sucrose in PBST,
and then incubated with culture supernatants of hybrid-
omas as primary antibodies. Bound antibodies were
detected using a 1:2500 diluted HRP-conjugated F(ab’)2
fragment anti-mouse Ig and an ECL Western blotting
detection reagent.
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